-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head to Head Analysis: Akili (NASDAQ:AKLI) and Femasys (NASDAQ:FEMY)
Head to Head Analysis: Akili (NASDAQ:AKLI) and Femasys (NASDAQ:FEMY)
Femasys (NASDAQ:FEMY – Get Rating) and Akili (NASDAQ:AKLI – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Femasys and Akili's net margins, return on equity and return on assets.
Get Femasys alerts:| Net Margins | Return on Equity | Return on Assets | |
| Femasys | -886.22% | -48.96% | -44.68% |
| Akili | N/A | -53.80% | -5.15% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Femasys and Akili, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Femasys | 0 | 0 | 3 | 0 | 3.00 |
| Akili | 0 | 1 | 4 | 0 | 2.80 |
Insider & Institutional Ownership
7.5% of Femasys shares are held by institutional investors. Comparatively, 78.0% of Akili shares are held by institutional investors. 20.8% of Femasys shares are held by company insiders. Comparatively, 20.4% of Akili shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Femasys and Akili's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Femasys | $1.18 million | 9.31 | -$7.54 million | ($0.79) | -1.18 |
| Akili | N/A | N/A | -$2.44 million | N/A | N/A |
Akili has lower revenue, but higher earnings than Femasys.
Volatility & Risk
Femasys has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Akili has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Summary
Akili beats Femasys on 6 of the 11 factors compared between the two stocks.
About Femasys
(Get Rating)
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
About Akili
(Get Rating)
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
Femasys (NASDAQ:FEMY – Get Rating) and Akili (NASDAQ:AKLI – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
费玛斯(纳斯达克：Femy-Get评级)和阿基利(纳斯达克：Akli-Get评级)都是小盘医疗公司，但哪只股票更好？我们将根据这两家公司的风险、估值、收益、盈利能力、股息、分析师建议和机构所有权等方面的实力进行比较。
Profitability
盈利能力
This table compares Femasys and Akili's net margins, return on equity and return on assets.
此表比较了Femasys和Akii的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Femasys | -886.22% | -48.96% | -44.68% |
| Akili | N/A | -53.80% | -5.15% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 费马西斯 | -886.22% | -48.96% | -44.68% |
| 阿基里 | 不适用 | -53.80% | -5.15% |
Analyst Recommendations
分析师建议
This is a summary of current recommendations and price targets for Femasys and Akili, as provided by MarketBeat.com.
这是MarketBeat.com提供的对Femasys和Akii的当前建议和目标价的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Femasys | 0 | 0 | 3 | 0 | 3.00 |
| Akili | 0 | 1 | 4 | 0 | 2.80 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 费马西斯 | 0 | 0 | 3 | 0 | 3.00 |
| 阿基里 | 0 | 1 | 4 | 0 | 2.80 |
Insider & Institutional Ownership
内部人与机构所有权
7.5% of Femasys shares are held by institutional investors. Comparatively, 78.0% of Akili shares are held by institutional investors. 20.8% of Femasys shares are held by company insiders. Comparatively, 20.4% of Akili shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Femasys 7.5%的股份由机构投资者持有。相比之下，Akii 78.0%的股票由机构投资者持有。Femasys 20.8%的股份由公司内部人士持有。相比之下，Akii 20.4%的股份由公司内部人士持有。强大的机构持股表明，对冲基金、大型基金管理公司和捐赠基金相信，一只股票有望实现长期增长。
Valuation and Earnings
估值和收益
This table compares Femasys and Akili's top-line revenue, earnings per share (EPS) and valuation.
该表格比较了Femasys和Akii的营收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Femasys | $1.18 million | 9.31 | -$7.54 million | ($0.79) | -1.18 |
| Akili | N/A | N/A | -$2.44 million | N/A | N/A |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 费马西斯 | 118万美元 | 9.31 | -754万元 | ($0.79) | -1.18 |
| 阿基里 | 不适用 | 不适用 | -244万元 | 不适用 | 不适用 |
Akili has lower revenue, but higher earnings than Femasys.
Akii的收入低于Femasys，但收入高于Femasys。
Volatility & Risk
波动性与风险
Femasys has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Akili has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Femasys的贝塔系数为-0.31，表明其股价的波动性比标准普尔500指数低131%。相比之下，Akii的贝塔系数为0.79，这表明其股价的波动性比标准普尔500指数低21%。
Summary
摘要
Akili beats Femasys on 6 of the 11 factors compared between the two stocks.
在比较两只股票的11个因素中，Akii有6个超过了Femasys。
About Femasys
关于Femasys
(Get Rating)
(获取评级)
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
生物医药公司Femasys Inc.专注于美国的女性保健市场。该公司开发了永久性节育解决方案，如FemBloc和FemChec；FemaSeed，一种人工授精解决方案；FemCerv，一种用于宫颈刮宫的活检设备；以及FemEMB，一种用于子宫内膜采样以支持子宫癌检测测试的候选产品。它还在美国、欧洲、加拿大、日本和国际上将FemVue盐分空气设备商业化。该公司向妇科医生、相关的医疗保健专业人员、女性保健提供者组织和生殖内分泌学家提供不孕不育产品。此外，它还提供非手术产品技术。Femasys Inc.成立于2004年，总部设在佐治亚州的苏瓦尼。
About Akili
关于阿基利
(Get Rating)
(获取评级)
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
Akii，Inc.是一家数字医药公司，开发用于认知障碍的数字疗法。它提供EndeavorRx，这是一种医生开出的基于视频游戏的治疗方法，旨在直接针对认知功能。该公司总部设在马萨诸塞州波士顿。
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
接受Femasys Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Femasys和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧